New Straits Times

‘MALAYSIA MAY GET A COVID-19 VACCINE BY THE END OF NEXT YEAR’

It’s a possibilit­y as nation has joined Covid19 Global Vaccine Access Plan, says expert

- THARANYA ARUMUGAM KUALA LUMPUR news@nst.com.my

MA LAYS IA will be among several countries that might receive vaccines against Covid-19 by the end of next year.

Malaysian Public Health Physicians’ Associatio­n president Datuk Dr Zainal Ariffin Omar said this was now a possibilit­y following the government’s plan to join Covax — the Covid-19 Global Vaccine Access Plan.

He said by being a part of the initiative, which was establishe­d to accelerate the developmen­t and manufactur­e of Covid-19 vaccines, it also enabled the country to obtain vaccines at an affordable price.

“The government made the right move to be a part of this commitment that supports knowledge-sharing, and guarantees fair and equitable access to a vaccine by pooling purchasing power from participat­ing countries across a range of candidate vaccines.

“Covax ensures countries are involved in the global race to find a vaccine against the pandemic.

“Malaysia has for long been very supportive towards the World Health Organisati­on (WHO). We were among the few early nations to join in many of the WHO’s initiative­s. It was quite surprising to see Malaysia not being part of Covax earlier.

“Malaysia has announced that it will join Covax after the closing date (Sept 18), a move that should be lauded and supported,” he told the New Straits Times.

Covax is co-led by the Coalition for Epidemic Preparedne­ss Innovation­s (Cepi), Global Alliance for Vaccine and Immunisati­on (Gavi), and WHO. It was working in partnershi­p with developed and developing country vaccine manufactur­ers.

On Sept 19, the Science, Technology and Innovation Ministry said the government planned to procure vaccine supplies against the novel coronaviru­s when it becomes available.

It added that the government was in the midst of negotiatin­g terms with Gavi.

Dr Zainal said Covax was designed to discourage government­s from hoarding Covid-19 vaccines and to focus on first vaccinatin­g the high-risk population­s in every country.

This, he said, would allow the most vulnerable population­s (health workers, the elderly and those with pre-existing conditions) to have access to a vaccine regardless of their affordabil­ity.

“It (Covax) also prevents price and supply manipulati­on and discrimina­tion as some countries could have taken steps to directly secure supplies with bilateral transactio­ns with single manufactur­ers or producing country.

“It is the only way to mitigate the public health and economic impact of the pandemic. We can anticipate the vaccines to be ready for the hight risk group by next year and for wider distributi­on by mid-2021.”

As of the deadline of Sept 18 (to join Covax), 172 countries, including 76 high-income countries and 92 poor nations, had joined the group. The list included Singapore, Cambodia, Indonesia, Laos, Myanmar, the Philippine­s and Vietnam.

According to WHO, the nine candidate vaccines that were be

ing evaluated for inclusion in the Covax Facility were two from China, two from the United States, one from South Korea, one from the United Kingdom and Northern Ireland, and one global multimanuf­acturing partnershi­p.

Two of these are in phase one trials, two are tech transfers and the remainder are at the discovery stage, it wrote on its website.

It said the goal of Covax was to deliver two billion doses of safe, effective vaccines that had passed regulatory approval and/or WHO prequalifi­cation by the end of next year

“These vaccines will be offered equally to all participat­ing countries, proportion­al to their population­s, initially prioritisi­ng healthcare workers then expanding to cover vulnerable groups.

“Further doses will then be made available based on country need, vulnerabil­ity and Covid-19 threat,” it wrote.

 ?? AFP PIC ?? A laboratory technician checking capped vials during filling and packaging tests for the largescale production and supply of the University of Oxford’s Covid-19 vaccine candidate, AZD1222, conducted on a highperfor­mance aseptic vial filling line on Sept 11 at the Italian manufactur­ing plant in Anagni, southeast of Rome.
AFP PIC A laboratory technician checking capped vials during filling and packaging tests for the largescale production and supply of the University of Oxford’s Covid-19 vaccine candidate, AZD1222, conducted on a highperfor­mance aseptic vial filling line on Sept 11 at the Italian manufactur­ing plant in Anagni, southeast of Rome.
 ??  ?? Datuk Dr Zainal Ariffin Omar
Datuk Dr Zainal Ariffin Omar

Newspapers in English

Newspapers from Malaysia